Proportion of youth aged 19 years and younger dispensed buprenorphine decreased 45 percent from 2015 to 2020
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Lower use of psychotropic, antihypertensive, and asthma medications observed; association attenuated by body mass index
Letters highlighting mandate to check PMP before prescribing can increase PMP search rates and PMP account-holding rates
Period prevalence of all antipsychotic prescriptions increased 3.3 percent per year from 2000 to 2019
Improvement in self-reported antiretroviral therapy adherence and decrease in viral load seen with intervention
Controversy over Aduhelm stretches back to its June 2021 approval by the U.S. Food and Drug Administration
Magnitude of association for finasteride and dutasteride with dementia decreased over time and became nonsignificant
More adverse dental outcomes seen with sublingual buprenorphine/naloxone compared with use of transdermal buprenorphine or oral naltrexone
Risk for death, unplanned hospital admission significantly lower for those taking AChEIs only or taking AChEIs and memantine